HOXA9 is a homeodomain-containing transcription factor that has an important role in hematopoietic stem cell expansion and is commonly deregulated in acute leukemias. A variety of upstream genetic alterations in acute myeloid leukemia lead to overexpression of HOXA9, which is a strong predictor of poor prognosis. In many cases, HOXA9 has been shown to be necessary for maintaining leukemic transformation; however, the molecular mechanisms through which it promotes leukemogenesis remain elusive. Recent work has established that HOXA9 regulates downstream gene expression through binding at promoter distal enhancers along with a subset of cell-specific cofactor and collaborator proteins. Increasing efforts are being made to identify both the critical cofactors and target genes required for maintaining transformation in HOXA9-overexpressing leukemias. With continued advances in understanding HOXA9-mediated transformation, there is a wealth of opportunity for developing novel therapeutics that would be applicable for greater than 50% of AML with overexpression of HOXA9.
INTRODUCTION
HOX proteins are a family of homeodomain-containing transcription factors that were first described in Drosophila for their ability to produce homeotic transformations-that is, changing one section of the body into another-when misexpressed during development. 1, 2 Since this early discovery, an entire field has been devoted in studying these master regulators of developmental processes and their role in disease. The 39 mammalian HOX genes are arranged into four parologous clusters on separate chromosomes, allowing for the tight transcriptional control required to establish the anterior-posterior body plan and assign tissue fate. 3, 4 As such, dysregulation of HOX genes results in a variety of developmental disorders and malignancies.
HOXA9 is of particular interest as it has been shown to be overexpressed in more than 50% of acute myeloid leukemias (AML) and is highly associated with poor prognosis. [5] [6] [7] [8] [9] A variety of upstream genetic alterations can lead to dysregulation of HOXA9, including MLL-translocations, NUP98-fusions, NPM1c mutations, CDX dysregulation and monocytic leukemia zinc-finger fusions. One challenge in defining the mechanisms through which HOXA9 overexpression contributes to AML is the relative lack of understanding of how HOX proteins regulate gene expression. Recent work suggests that HOXA9 binding specificity is achieved through a combination of motif affinity, interactions with cofactor and collaborating proteins, and context-specific chromatin accessibility. [10] [11] [12] In addition, multiple studies have established that HOXA9 can both activate and repress downstream gene expression, though the mechanisms for these actions are relatively unknown. Finally, increasing efforts are being made toward identifying the critical downstream targets of HOXA9 required for transformation in AML. In this review, we will highlight recent advances in understanding the role of HOXA9 in leukemia and discuss important questions that remain in the field.
REGULATION OF HOX GENE EXPRESSION
During development, HOX genes follow both a temporal and spatial pattern of expression, such that 3′ HOX genes are expressed earliest in the embryo and in the anterior regions, while 5′ HOX genes are expressed at later stages and more posteriorly. 3, 4 The tight regulation of HOX expression is the coordinated effort of a variety of factors including epigenetic regulators, early developmental transcription factors and long non-coding RNAs (lncRNAs). [13] [14] [15] Additionally, it is becoming clear that the 3D localization of the HOX loci within the nucleus also has an important role in coordinating expression. 16, 17 The two master epigenetic regulators of HOX gene expression, including HOXA9, belong to the trithorax and the polycomb group histone methyltransferases, which activate and repress transcription respectively (Figure 1a) . 18 The mixed lineage leukemia (MLL) methyltransferase positively regulates HOXA9 expression by trimethylating histone 3 lysine 4 (H3K4me3) at its promoter. 19 This activity is directly antagonized by the sequential activity of polycomb repressive complexes PRC1 and PRC2, responsible for trimethylating histone 3 lysine 27 (H3K27me3). 18 Studies in both Drosophila and mice have found that, similar to mutations in individual HOX proteins, mutations in trithorax proteins/ MLL can lead to homeotic transformations. 20 In addition, loss of MLL in mouse models leads to profound impairment of hematopoiesis. 21, 22 As such, alterations in the activity or expression of MLL or PRCs can lead to a variety of both developmental disorders and hematopoietic malignancies.
Along with MLL and PRC methyltransferases, the CDX family of transcription factors also has an important role in regulating HOXA9 expression during embryonic hematopoiesis. 25 CDX1, 2 and 4 are members of the unclustered ParaHox class of homeobox transcription factors that, like HOX proteins, contain a DNAbinding homeodomain. 26 Studies in various model systems show that CDX proteins activate expression of HOX genes primarily in the A and B clusters, though the mechanisms for this regulation are unknown. [27] [28] [29] In addition, studies in zebrafish have established a requirement for CDX4 in maintaining HOX gene expression during embryonic hematopoiesis. 27, 30 Along with epigenetic modifiers and early transcription factors, HOX gene expression is also regulated by lncRNAs, though direct regulation of HOXA9 by lncRNAs has yet to be established. LncRNAs can activate or repress HOX genes through the interaction and recruitment of trithorax and polycomb histone modifying complexes. Both HOTTIP (HOXA transcript at the distal tip) and Hoxb5b6as, lncRNAs expressed from the 5′ region of HOXA13 and the Hoxb5/6 locus respectively, can interact with trithorax group proteins to maintain active transcription of their corresponding gene clusters. 15, 31 Conversely, HOTAIR (HOX antisense intergenic RNA) is a lncRNA that is transcribed from the HOXC locus that functions to maintain repression of the HOXD locus through interaction with PRC2 and histone demethylase LSD1. 32 Although there are currently no studies of HOXspecific lncRNAs in leukemia, misexpression of these lncRNAs has been observed in a variety of solid tumors, suggesting a possible role in hematopoietic malignancies as well. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] As technologies for identifying long-range chromatin interactions and mapping genome-wide chromosome conformation continue to improve, it is becoming clear that the chromosomal conformation and physical location of genes in the nucleus contributes greatly to the regulation of global gene expression. 43 Recent work has established that the 3D localization of the HOX genes within the nucleus has an important role in their regulation. Studies in Drosophila have shown that subsets of HOX genes frequently colocalize in distinct nuclear foci, called polycomb repressive bodies, leading to coordinated repression of these targets. 16, 17 DNA regulatory elements that contribute the physical interaction and colocalization of these loci are required for effective expression silencing; however, these interactions are also topographically constrained by chromatin architecture. 17 
ROLE OF HOXA9 IN HEMATOPOIESIS
Upon completion of development, most HOX genes are transcriptionally silenced; however, certain members of the A, B and C clusters are important regulators of adult hematopoiesis. 44, 45 Expression of HOX genes in hematopoiesis follows a pattern similar to that during development, such that anterior HOX genes (HOX1-6) are expressed in early uncommitted progenitors, while posterior HOX genes (Hox7-13) are expressed in myeloid and erythroid-committed CD34+ cells. 45 As cells become fully mature and lose CD34 positivity, HOX gene expression is silenced. The functional redundancy of many of the HOX proteins is such that knockout models of many HOX genes result in only mild hematopoietic phenotypes. Loss of individual HoxB genes and Figure 1 . HOXA9 regulation in normal hematopoiesis and leukemia. (a) During development and hematopoiesis, expression of HOXA9 is primarily regulated by the antagonistic actions of the MLL complex and polycomb repressive complex. These histone methytransferases deposit the activating H3K4me3 and repressive H3K27me3 marks respectively. CDX proteins also have a role in HOXA9 regulation, through mechanisms that are not well defined. (b) A variety of upstream genetic alterations lead to the upregulation of HOXA9, which is essential for the acute leukemias that result from these alterations. Decreased expression of EZH2 and chromosomal translocations leading to MLL-fusion proteins result in activation of HOXA9 expression through dysregulated chromatin modification. Cytoplasmic mutations of NPM1, fusion proteins with NUP98 and overexpression of CDX2 and CDX4 also lead to upregulation of HOXA9 through mechanisms that remain to be completely defined. HOXA9 likely goes on to promote transformation through the activation of proproliferative genes and the repression of genes required for cellular differentiation.
even the entire HoxB locus leads to only slight reduction in bone marrow cellularity, without significantly affecting the ability of hematopoietic stem cells (HSCs) to repopulate bone marrow. [46] [47] [48] [49] [50] Similarly, loss of HOX genes in the A and C clusters leads to mild lineage skewing affecting primarily the erythroid compartment. [51] [52] [53] [54] [55] HOXA9 is the most highly expressed HOX gene in the hematopoietic compartment, and as such Hoxa9 − / − mice display the most dramatic hematopoietic phenotype. 56, 57 Although loss of Hoxa9 in murine models leads to only mild pancytopenia, competitive repopulation assays uncover a significant reduction in Hoxa9
− / − fetal liver HSC repopulation capacity compared with normal HSCs. 58 In addition, overexpression of HOXA9 results in expansion of HSCs and early progenitors, leading to myeloproliferative phenotypes in mice. 59 It should be noted that this myeloproliferation will not progress to AML in the absence of additional genetic factors, such as the co-expression of its cofactor MEIS1 or fusion to nucleoporin protein Nup98. In the case of MEIS1, which is almost always expressed at high levels along with HOXA9 in human disease, co-expression leads to a rapidly fatal leukemia in mice with an average latency of 40-60 days. 50, 60, 61 
DYSREGULATION OF HOXA9 IN ACUTE LEUKEMIA
The most broadly studied diseases with dysregulation of HOX genes are acute leukemias. 59, 62, 63 In most cases, HOX genes are expressed at high levels in acute leukemias, with HOXA9 in particular having a 2-8-fold higher expression in AML compared with healthy controls in~50% of cases. 6, 64 High expression levels of HOX A and B genes has been associated with an intermediate to unfavorable prognosis in acute leukemias. 5, 7, 9, 65 In one study, HOXA9 was found to be the single strongest predictor of poor prognosis in AML. 8 It should be noted that high expression of HOXA9 often coincides with upstream genetic alterations that themselves have negative prognostic values in AML. As such it is difficult to determine if HOXA9 is a predictor of poor prognosis independently of concurrent genetic alterations. On the other hand, HOXA9 has been shown to directly regulate critical downstream genes such as Bcl-2 and Ink4a/ARF/Ink4b, which themselves are linked to poor outcomes, providing plausible evidence for a direct role for HOXA9 in determining prognosis in AML. 66, 67 Additionally, the wide variety of upstream genetic alterations that lead to overexpression of HOXA9 suggests that it serves as a common pathway for leukemic transformation ( Figure 1b ).
MLL-fusion proteins
About 10% of acute leukemias harbor chromosomal translocations at the 11q23 locus involving MLL, that are associated with an aggressive clinical course. 68 There have been over 60 different fusion partners of MLL identified, although 90% of these translocations involve one of nine partners: AF1P (EPS15), AF4 (AFF1), AF6 (MLLT4), AF9 (MLLT3), AF10 (MLLT10), AF17 (MLLT6), ENL (MLLT1), ELL and SEPT6. 69 In addition, a partial tandem duplication event can occur within the N-terminus of MLL, which is observed in~10% of cytogenically normal AML. 70 MLL fusion proteins constitutively up regulate HOXA9 expression, which is both required and sufficient for maintaining leukemic transformation. 71, 72 The upregulation of HOXA9 is directly linked to histone 3 lysine 4 trimethylation at promoters by MLL-fusion proteins; however, there has also been documentation of DNA hypomethylation at various HOX promoters in MLL-fusion leukemias.
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NUP98-fusion proteins NUP98 is a member of the nucleoporin family of proteins that coassociates to form multisubunit channels in nuclear membranes. These nuclear pore complexes were first described for their role in facilitating transfer of metabolites and molecules between the cytoplasm and nucleus. 74 Recent work has found that nuclear pore complexes also have a critical role in defining the chromatin landscape in the nucleus and facilitating gene transcription from euchromatic regions of the genome. 75 Nucleoporins are involved in chromosomal translocations that can lead to acute leukemias, most commonly involving NUP98. 76 The most potent NUP98 oncogenes are those fused to one out of eight homeobox partners, including HOXA9. 77 These fusions in turn lead to general upregulation of additional HOX genes including HOXA5, HOXA7, HOXA9 and HOXA10, which contribute to leukemogenesis. 78 In addition, fusions with NSD1 and JARID1A upregulate HOXA and HOXB in AML and AMKL. 79, 80 It is noteworthy that, aside from increases in HOX genes, these leukemias have an expression signature distinct of that from MLL-rearranged leukemias. 80 
NPM1c
One of the most common genetic abnormalities in adult AML is mutation in the chaperone protein Nucleophosmin1. 81 Although under normal conditions NPM1 resides primarily in the nucleus, mutations seen in AML result in cytoplasmic localization of NPM1. 82 Cytoplasmic NPM1 (NPM1c) upregulates the expression of HOXA9, HOXA10 and MEIS1, although the precise mechanism is currently unknown. 83 One possible mechanism is that HOXA9 is upregulated as a result of the cytoplasmic sequestration of HEXIM1 by NPM1c, leading to the activation of the MLL transcriptional partner P-TEFb. [84] [85] [86] Studies in mice have also established that NPM1c can collaborate with Flt3, Csf2 and Rasgrp1 in vivo to produce leukemias with long latency. 87 Other mechanisms of HOXA9 dysregulation Many additional upstream genetic alterations lead to HOXA9 dysregulation in acute leukemia. Deletions or decreased expression of polycomb protein EZH2 leads to leukemia with upregulation of HOXA9. 88 Conversely overexpression of Cdx proteins, in collaboration with Meis1, leads to leukemias with high levels of Hox expression. 89, 90 Monocytic leukemia zinc-finger fusion proteins can directly upregulate HOXA9/10 and MEIS1 in AML by colocalizing at promoters with the histone acetyltransferase, BRPF1. 91 Chromosomal translocations generating the CALM-AF10 fusion protein, as well as those involving the T-cell receptor promoter and the HOXA locus, lead to HOX upregulation in T-ALL. 78, 92 Hoxa9 also collaborates with E2A-PBX1 in murine B-cell leukemia to repress B-cell genes and activate Flt3. 93 Finally, mutations in ASXL1 are common in myelodysplastic syndromes and are associated with high expression of HOXA9, mediated by inhibition of the PRC2. 94 
MECHANISMS OF HOXA9-REGULATED GENE TRANSCRIPTION
It is becoming clear that HOX genes carry out their highly specialized function through association at promoter distal, lineage-specific cis-regulatory elements; however, understanding how HOXA9 and other HOX proteins are targeted to these sites has been challenging. 12, 95 As discussed below, all HOX proteins share a highly homologous DNA-binding homeodomain, which because of its short recognition sequence cannot account for the distinct subpopulations of target genes seen in development and hematopoiesis. Additional sequence specificity is likely achieved through association with other DNA-binding cofactors and collaborator proteins. These proteins may also function to establish areas of chromatin accessibility in a given cell type and recruit and stabilize HOX proteins at various loci. Furthermore, the downstream activity of HOXA9 to activate or repress target gene expression may be modulated by these cofactors and collaborators. Below we will discuss what is known about DNA-binding properties of HOX proteins and known binding partners that confer specificity to HOX proteins, with a focus on recent advances in the field.
HOXA9 regulates gene expression through enhancer binding
The homeobox family of transcription factors is defined by the presence of a DNA-binding homeodomain, which is highly homologous within the 39 mammalian HOX proteins and conserved across species. Early studies have found that this 60-amino acid region makes direct contact with DNA via four critical amino acids-aa47, 50, 51 and 54-within the third alpha helix of the homeodomain. 96 Interestingly, nearly all homeodomains contain the same residues in these critical positions. 97 In addition, comprehensive work has established that all HOX homeodomains bind highly similar AT-rich DNA motifs. [98] [99] [100] In Drosophila, this TAATNA motif occurs over 100 000 times throughout the genome, and thus cannot explain the distinct subsets of target genes for each HOX protein. 99 Conversely, the presence of this recognition sequence seems critically important for DNA binding as a chromatin immunoprecipitation (ChIP)-seq study of genomewide HOXA9 binding sites in transformed myeloblasts found that 498% of sites contain a HOX motif. 101 Studies have found that the small differences in homeodomains themselves can confer unique properties to HOX proteins. 102, 103 For example, swapping the homeodomains of Hoxa1 and Hoxa9 conferred leukemogenic properties to Hoxa1 while abolishing those of Hoxa9. 104 This phenomenon required the presence of the N-terminal region and PBX cofactor interaction motif, though these regions were interchangeable between Hoxa1 and Hoxa9. There are additional examples of this phenomenon in HoxD proteins with respect to motor neuron fate and rib development. 105, 106 Interestingly, the contributions of the homeodomain to specific phenotypes may also be the result of interaction with different cofactors, as this region has been found to mediate protein-protein interactions in addition to DNAbinding. For example, Cdx1 and Foxo1a have been shown to interact with the homeodomain regions of HOX proteins. 107 In addition to the motif affinity of a particular homeodomain, gene regulation specific to a single HOX protein likely results from the combination of chromatin accessibility and the subset of cofactors and collaborators expressed in the specific cellular context. ChIP of the Drosophila HOX protein ultrabithorax (Ubx) across various stages of development indicates that binding is strongly influenced by chromatin accessibility. 108, 109 In the hematopoietic system, early factors such as PU.1 and C/EBPα are known to establish areas of relaxed chromatin that allow for signaling-dependent recruitment of various transcription factors, likely mediated by SWI/SNF chromatin remodelers. 110, 111 Interestingly, both C/EBPα and SWI/SNF factor Brg1 colocalize with HOXA9 at hundreds of promoter distal regulatory regions throughout the genome of HOXA9/MEIS1 transformed myeloblasts, suggesting that chromatin accessibility likely have a key role in the targeting of HOXA9 to specific genomic loci. 6, 101 This targeting is then further honed through specific protein-protein interactions with cofactors and collaborator proteins that are expressed along with HOXA9 in a particular cellular milieu.
HOXA9 interacting partners
It is well established that HOXA9 and other HOX proteins bind DNA and regulate downstream gene expression along with a small subset of cofactor proteins. 112 The most well characterized cofactors are members of the Three-amino-acid-loop-extension (TALE) family of proteins including Pbx1-4, Meis1-3 and Prep1-2. 113 In addition, HOX proteins can homo and heterodimerize to aid in diversity and specificity of binding. 114 Whether HOX proteins co-bind with Meis or with Prep proteins subdivides clusters of binding sites. 115 There is also evidence that binding may be sequential such that TALE factors initially bind at regulatory elements to promote the deposition of poised chromatin marks, whereby subsequent recruitment of HOX proteins results in transcriptional activation. 116 Indeed, the majority of sites co-bound by HOX and PBX proteins show histone H3K27 acetylation and not trimethylation, suggesting that complexes containing HOX/PBX may be primarily transcriptional activators. 99 Additional studies have established that interactions with TALE cofactors are not required at some loci and HOX proteins themselves may homo or heterodimerize at these sites. 117 Furthermore, there is new evidence of antagonism between TALE proteins and HOX proteins at specific genomic regions. 118 In the setting of leukemia, the most critical cofactor of HOXA9 is the TALE protein, MEIS1. MEIS1 expression parallels that of HOXA9 during hematopoiesis, where it is highly expressed in early progenitors and subsequently downregulated during terminal differentiation. 44 Like HOXA9, MEIS1 is directly upregulated by MLL-fusion proteins in both AML and acute lymphoblastic leukemia and is required for maintaining transformation. 19, 119, 120 Futhermore, MEIS1 is almost always expressed at high levels along with HOXA9 in non-MLL-translocated leukemias, where high expression correlates with poor prognosis. 60, 121, 122 Multiple studies have implicated that HOXA9 and MEIS1 have both a synergistic and causative role in acute leukemias. More than 90% of leukemias that arise in the BZH2 murine retroviral mutagenesis model have independent viral integrations that result in upregulation of both Hoxa9 and Meis1. 123 In addition, murine models of HOXA9-mediated leukemia require co-expression of MEIS1 to produce an aggressive disease. 50, 61 This requirement is likely secondary to cooperation between HOXA9 and MEIS1 at enhancers on the genome-wide level. Indeed, nearly half of HOXA9 binding sites in HOXA9/MEIS1-transformed myeloblasts are co-bound by MEIS1, including sites associated with pro-leukemic target genes. 101 At these co-bound sites, MEIS1 helps to recruit transcription regulatory machinery. Indeed MEIS1 has been shown to associate with CREB and CBP in a GSK-3-dependent manner, which is required for maintaining the MLL leukemia stem cell transcriptional program. 124 This interaction can be targeted using GSK-3 inhibitors, leading to inhibition of cells transformed by MLLfusion proteins or HOXA9/MEIS1, thus presenting a novel therapeutic target for leukemias with high expression of HOXA9. [124] [125] [126] More recent work has also established PBX3 as a critical cofactor required for cytogenetically abnormal AML, presenting an additional target for future therapies. 127 Results are promising as the small molecule inhibitor HXR9, which targets the HOX/PBX interaction, was shown to inhibit cell growth and promote apoptosis in AML cell lines that expressed high levels of HOXA9 and PBX3. 127, 128 It has been proposed by Mann et al. 99 that context-specific collaborator proteins provide a final level of binding specificity to HOX complexes to allow for their specific actions on gene expression. These tissue-specific interactors bind along with HOX proteins and TALE cofactors to establish areas of chromatin accessibility, provide stability in DNA binding and help modulate the downstream activity of HOX complexes. 129 Recent studies have focused on identifying potential collaborator proteins in a variety of systems. Yeast two-hybrid approaches have been used to identify binding partners for Hoxa1 and Hoxa9 (Lambert et al. 130 and unpublished). In addition, our group has identified interactors of Hoxa9 in transformed myeloblastic cell lines using co-immunoprecipitation with mass spectrometry, followed by western blot confirmation. 101 The transcription factors C/EBPα and Stat5b were both identified in this binding partner screen, along with the chromatin-remodeling enzyme Brg1 and multiple other members of the SWI/SNF complex. Interestingly, each of these putative collaborators are known to be mutated or otherwise dysregulated in leukemia, providing further basis for studying their functional interplay with HOXA9. [131] [132] [133] In addition, recent work has shown that C/EBPα is required for HOXA9-mediated leukemogenesis in vitro and in vivo. 6 Multiple other proteins that physically interact with HOXA9 have been identified by using various techniques, as summarized in Table 1 . With these approaches, some themes in collaborator proteins are surfacing. Many are lineage-specific factors known for general priming of enhancer regions of the genome, while others are involved in signal transduction.
Following targeting to specific sites, HOX complexes most likely control downstream gene expression through the interaction with histone modifying machinery. Both Hoxa9 and Meis1 have been shown to recruit the histone acetyltransferase p300/CBP to mediate activation of downstream targets. 124, 134, 135 Recent work also established that Hoxa9 interacts with the histone methyltransferase G9a and that this interaction is required for aggressive disease in mouse models of leukemia. 136 Similarly, both activation and repression domains have been defined in Hoxa10 (and other Hox10 proteins) that facilitate interaction with CBP and HDAC2 respectively. 137, 138 HOX proteins can also interact with other enzymes and machinery leading to their own modification.
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HOXA9 is phosphorylated by protein kinase C in the N-terminal region of its homeodomain, leading to decreased DNA binding and promoting myeloid differentiation. 140 In addition, HOXA9 can be methylated by PRMT5 in a TNFa-dependent manner, which promotes downstream expression of E-selectin and VCAM-1.
141

TRANSCRIPTIONAL TARGETS OF HOXA9
In addition to characterizing the mechanisms through which HOXA9 regulates downstream gene expression, identifying the downstream targets that mediate leukemic transformation is critically important. Many efforts have been made using both genome-wide approaches and site-specific experiments for identifying these important targets in both development and disease (Table 2) .
Targets in leukemia Considerable progress has been made toward understanding HOXA9-mediated leukemogenesis through the identification of the genome-wide binding sites of HOXA9 and MEIS1 in transformed myeloblastic cells. ChIP-seq experiments using murine bone marrow transduced with HOXA9 and MEIS1 identified thousands genomic regions that bind HOXA9, MEIS1 or both, and these regions showed a high degree of evolutionary conservation. 6, 101 Over 90% of the binding sites are located in distal intergenic regions (410 kb from transcriptional start sites) or gene introns, while o 3% are located within 3 kb of promoter regions. These studies also identified multiple pro-leukemic targets with cis-regulatory regions bound by HOXA9, including Erg, Flt3, Lmo2 and Myb. In addition, both microarray and RNA-seq studies in models with inducible expression of HOXA9 have identified hundreds of genes with significant changes in expression following the loss of HOXA9.
6,101 Interestingly, near equal numbers of genes are activated and repressed by HOXA9, suggesting that HOXA9 may have an important role in both activating and inhibitory transcriptional regulation complexes. Consistent with its role as a proto-oncogene, HOXA9 generally upregulates proliferative genes, while suppressing expression of myeloid differentiation and inflammatory genes.
Many HOXA9 targets have been studied individually and found to have important roles in HOXA9-mediated leukemogenesis. Knockdown of Lmo2 impairs growth of leukemic cells and high levels of Lmo2 predict poor prognosis in patients.
142 Hoxa9 activates Bcl-2 expression, which is required for transformation by Hoxa9, Nup98-Hoxa9 and MLL. Furthermore, loss of Bcl-2 leads to improved survival in mouse models of Hoxa9/Meis1-transformed leukemia. 143 MLL-ELL upregulates Fgf2 expression in a Hoxa9/a10 dependent fashion, leading to increased proliferation and cytokine hypersensitivity. 88, 91 Hoxa1 and Hoxa9 regulate Rac1 activity by directly upregulating Vav2 expression. 144 In very recent work, Igf1 has also been identified as a direct target of HOXA9 required for leukemic transformation. 145 Finally, multiple studies have implicated a role for Hoxa9 in the regulation of Ink4a/b expression, critical mediators of HSC self-renewal, apoptosis and oncogene-induced senescence whose expression leads to a block in cell cycle at the G1 phase. 146 The Inka/b locus is commonly deleted or silenced in acute lymphoid leukemias. [147] [148] [149] Interestingly Hoxa9 has been shown to repress Ink4a expression to overcome oncogene-induced senescence during transformation by AML1-ETO in Bmi1
− / − cells, as well as in Hoxa9/Meis1 transformed cells. 6, 150 Currently genome-wide studies of HOXA9 binding have been constrained to overexpression models due to lack of ChIP-grade antibodies for endogenous HOXA9 in either human or murine cells. Although studies in transformed cells have led to significant advances in our understanding of the role of HOXA9 in leukemia, questions remain with regard to the function of HOXA9 in normal hematopoiesis. One of the more interesting unanswered questions Non-transcriptional roles of Hoxa9 In addition to acting as a classical transcription factor regulating downstream gene expression, HOXA9 may also have nontranscriptional functions that are critical for its role in malignancy. 151 For example, Hoxa9 can act as an E3 ligase for DNA replication inhibitor Geminin, leading to its degradation, which contributes to Hoxa9-mediated transformation. 152, 153 Conflicting reports however also find that Hoxa9-Geminin binding can sequester Hoxa9 thereby inhibiting its transcriptional activity. 154 Alternate mechanisms have been described for other HOX proteins as well. For example, Hoxa2 can indirectly stabilize p53 by binding to p53's E3 ubiquitin ligase, RCHY1, leading to the degradation of RCHY1. 155 Hoxa7 and Hoxa14 can bind to the initiation factor eIF4E in liver cancer, potentially affecting the nuclear transport of eIF4E-dependent transcripts like c-myc, fgf2, vegf, ornithine decarboxylase and cyclin-D1. 156 Finally, the yeast two-hybrid screen of Hoxa1 interactors identified many putative binding partners involved in signal transduction, cell adhesion and vesicular trafficking, pointing to additional non-transcriptional roles for this and other HOX proteins. 130 
CONCLUSIONS
As more and more malignancies involving dysregulation of HOX genes are identified, it is clear that the mechanisms through which HOX proteins exert their function need to be better defined. HOXA9 is of particular interest as it is overexpressed in over 50% of AMLs, as well as B-and T-cell leukemias, and its high level of expression is associated with poor prognosis. Research to date suggests that HOXA9 acts to modulate the activity of distal regulatory elements through recruitment of histone modifying and transcriptional machinery that likely act at promoters via longrange chromatin interactions, thereby up regulating a set of proleukemogenic target genes while repressing others involved in processes such as cellular senescence. Identifying new posttranslational modifications and protein-protein interactions required for HOX function is likely to be a promising avenue for identifying new therapeutic targets along with the identification of drug-amenable HOX targets that are essential for leukemia.
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